Navigation Links
Study Suggests Invega Helps Patients With Schizophrenia Maintain,,,Symptom Control

52-Week Trial Maintained Improvement in Personal and Social Performance

COLORADO SPRINGS, Colo., March 30, 2007 /PRNewswire/ -- Longer-term treatment with INVEGA(TM) (paliperidone) Extended-Release Tablets, a new once daily oral medication for schizophrenia, helped many patients effectively control their symptoms and maintain their improvements in personal and social functioning.

These latest data are from a large, open label, international clinical trial sponsored by Janssen, L.P., the U.S. marketer of INVEGA, and were presented today at the International Congress on Schizophrenia Research (ICOSR). INVEGA was approved last December by the U.S. Food and Drug Administration for the treatment of schizophrenia.

"Schizophrenia imposes serious, lifelong psychological, physical, social, and economic burdens on patients, caregivers and heath care systems worldwide," said Herb Meltzer, MD, Bixler/May/Johnson Professor of Psychiatry & Pharmacology at the Vanderbilt University School of Medicine. "I am encouraged by the results of this pooled analysis because of the need for antipsychotic treatment options that provide effective symptom control, good tolerability, and which help to sustain the ability of patients to function over the long term."

In a pre-planned analysis, researchers evaluated data from 1,083 patients at 168 centers across North America, Europe, Asia, South Africa, and 12 other countries in the open-label extension (OLE) of three similarly designed six- week double-blind studies. In the 52-week OLE phase of the studies, the patients maintained effective symptom control and the improvement in personal and social performance achieved during the six-week double-blind phase.

These studies provided longer-term follow-up to the three previously completed six-week, placebo-controlled trials that demonstrated efficacy and
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:7/29/2014)... and TORONTO ... Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical ... development of improved novel formulations and alternative ... announces expansion of its pharmaceutical development implementing ... direction includes large molecule drugs that will address ...
(Date:7/29/2014)... Mass., July 29, 2014 Cynosure, Inc. ... markets laser- and light-based aesthetic treatment systems for high-volume ... ended June 30, 2014. Second-quarter 2014 financial results incorporate ... on June 24, 2013. Second-Quarter ... increased 45% to $72.6 million , Non-GAAP net ...
(Date:7/29/2014)...  Novation, a VHA and UHC company, today ... features that automate key health care supply chain ... Association.  The new and enhanced ... Value Analysis, Item Master and Formulary – are ... most critical challenges brought on by health care ...
Breaking Medicine Technology:EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 2EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 3EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 4Cynosure Reports Second-Quarter 2014 Financial Results 2Cynosure Reports Second-Quarter 2014 Financial Results 3Cynosure Reports Second-Quarter 2014 Financial Results 4Cynosure Reports Second-Quarter 2014 Financial Results 5Cynosure Reports Second-Quarter 2014 Financial Results 6Cynosure Reports Second-Quarter 2014 Financial Results 7Cynosure Reports Second-Quarter 2014 Financial Results 8Cynosure Reports Second-Quarter 2014 Financial Results 9Cynosure Reports Second-Quarter 2014 Financial Results 10Cynosure Reports Second-Quarter 2014 Financial Results 11Cynosure Reports Second-Quarter 2014 Financial Results 12Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 2Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 3Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 4Breakthrough Novation Applications Empower Children's Hospital Association Members to Lower Costs, Increase Quality 5
... 2011 PediaVision today announced that Loma Linda ... the State of California to receive the revolutionary ... University,s Department of Ophthalmology is offering free vision ... the support of First 5 Riverside , ...
... small businesses struggle to afford health benefits, a ... Health Benefits regulations could include special interest protections that ... costs, the Pharmaceutical Care Management Association (PCMA) ... for thousands of small businesses throughout America. ...
Cached Medicine Technology:Loma Linda University Expands Vision Screening Program With Revolutionary New Screening Device, Spot 2Loma Linda University Expands Vision Screening Program With Revolutionary New Screening Device, Spot 3Loma Linda University Expands Vision Screening Program With Revolutionary New Screening Device, Spot 4Some Essential Benefits Rules Could Worry Small Businesses 2
(Date:7/29/2014)... The report, “Heat Transfer Fluids Market by Type ... & Others), by Application (Oil & Gas, Chemical, CSP, ... & Forecasts to 2019” defines and segments the global ... of the global consumption in terms of volume and ... spread through 199 page sand in-depth TOC on"Heat Transfer ...
(Date:7/29/2014)... New York (PRWEB) July 29, 2014 ... mount in U.S. courts, Bernstein Liebhard LLP notes that ... medications in men with Type 2 diabetes. The research, ... Endocrinology & Metabolism on June 30th, involved 88 men ... had mild to moderate aging male symptoms and erectile ...
(Date:7/29/2014)... negotiations may depend on more than diplomacy. When it comes ... according to a new study. Researchers found ... for themselves than men with narrower faces. However, having ... require collaboration and compromise, the researchers found. "We negotiate ... not just the big things, like a car or a ...
(Date:7/29/2014)... Society of America (GSA) and the National Center ... PhD, of Columbia University as the 2014 recipient of ... Aging. , This award recognizes and honors the seminal ... field of creativity and aging shifted the conceptual focus ... potential. Cohen inspired individuals to approach longevity asking what ...
(Date:7/29/2014)... in boys with fragile X syndrome tend to ... study of the inherited disorder to date has ... everyday social and practical skills, including communication, socialization, ... getting dressed. In this study, socialization emerged as ... in that it did not decline as much ...
Breaking Medicine News(10 mins):Health News:Heat Transfer Fluids Market Expected to Grow 641,218.19 Tons by 2019 – New Report by MarketsandMarkets 2Health News:Heat Transfer Fluids Market Expected to Grow 641,218.19 Tons by 2019 – New Report by MarketsandMarkets 3Health News:Heat Transfer Fluids Market Expected to Grow 641,218.19 Tons by 2019 – New Report by MarketsandMarkets 4Health News:As Testosterone Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Questioning Effectiveness of Low Testosterone Therapy in Diabetics 2Health News:As Testosterone Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Questioning Effectiveness of Low Testosterone Therapy in Diabetics 3Health News:As Testosterone Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Questioning Effectiveness of Low Testosterone Therapy in Diabetics 4Health News:Wider Face May Give You an Edge in Negotiations 2Health News:Charon to receive 2014 Gene D. Cohen Award 2Health News:Socialization relative strength in fragile X longitudinal study 2
... , THURSDAY, Jan. 27 (HealthDay News) -- Most ... at home, and quickly learn which types of brand-name fast ... In one experiment, the mothers of 67 children, aged 3 ... and listed foods high in sugar, fat and salt. The ...
... , THURSDAY, Jan. 27 (HealthDay News) -- Modern ... research suggests. An ancient human toolkit with hand axes, ... east Africa -- but not the Middle East -- was ... that the toolkit dates back 100,000 to 125,000 years, researchers ...
... Washington, DC, January 27, 2011 Screening patients in ... (MRSA) produces cost savings for the whole hospital, according ... published in the February issue of the American ... APIC - the Association for Professionals in Infection Control ...
... , THURSDAY, Jan. 27 (HealthDay News) -- Work-related ... has found. Israeli researchers gave hearing tests to 298 ... harmful noise and found that 99 of the workers had ... hearing problems tended to be older and to have been ...
... BEER SHEVA, ISRAEL January 27, 2011 -- A ... researchers indicates that physicians who give second opinions may ... factors. In the study, the researchers presented ... a national sample of orthopedic surgeons and neurologists. Some ...
... (RA) patients who failed to respond to methotrexate were ... an oral spleen tyrosine kinase (Syk) inhibitor that is ... and cartilage destruction. In the current study, RA patients ... In contrast to the prior study, however, fostamatinib was ...
Cached Medicine News:Health News:Kids Fed Unhealthy Foods Learn to Prefer Them 2Health News:Ancient Toolkit Holds Clues to Migration of Early Man 2Health News:Study finds MRSA screening saves hospitals money 2Health News:Ben-Gurion U. researchers determine that a first medical opinion can influence the second 2Health News:Fostamatinib proven to be safe but not effective 2
... ENDOPATH EZ45 Endoscopic Linear Cutter has application ... surgical procedures for transection, resection, and/or creation ... staple line or tissue buttressing materials such ... reloaded seven times for a total of ...
... Linear Cutters provide a 45mm staple and ... the device suitable for many minimally invasive ... transection, resection, and/or creation of anastomoses in ... ,The LONG45A Endocutter has a shaft ...
ACUCLIP Endoscopic Right-Angle Multiple Clip Applier, 10 mm Shaft Diameter with 20, 8 mm Titanium Clips...
Insert only, Pilling-Weck medium clip size...
Medicine Products: